Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

#4242

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Aim(s): We set up a retrospective study using prospectively-collected data from the Belgian Group of Digestive Oncology DNET and NETwerk’s Oncobase database, to analyse the efficacy of consecutive treatment with Everolimus and Sunitinib and the effect of sequence on median overall survival (mOS) and median progression-free survival (mPFS) in pNET and describe the adverse events (AEs).

Materials and methods: Clinicopathological data from all advanced pNET patients, receiving either Everolimus as second-line followed by Sunitinib (EverSun group) or vice versa (SunEver group) were collected. mOS was calculated from start of second-line treatment until death or lost to follow-up, mPFS1 until progression or end of 1st targeted therapy and mPFS2 until progression or end of 2nd targeted therapy. Data is analysed using R.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,